cancers

IMPACT FACTOR 4.5

Indexed in: PubMed

CITESCORE 8.0

an Open Access Journal by MDPI

Advances in TNBC: New Markers for Innovative Treatments

Guest Editor:

Dr. Pia Giovannelli
Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 Naples, Italy

Deadline for manuscript submissions:
15 December 2024

Message from the Guest Editor

Triple-negative breast cancer (TNBC) is a breast cancer subtype characterized by the lack of estrogen receptor (ER), progesterone receptor (PR), and the absence of type 2 epidermal growth factor receptor (HER-2) overexpression. This feature makes TNBC a hard-to-treat tumor. To date, chemotherapy is the first-line treatment, but many TNBCs only partially respond to it.

Many molecules, such as EGFR, PI3K, PARP, MEK, and histone deacetylase (HDAC), are mutated or hyperactivated, while others, for instance, AR and ERb, control growth and spreading, thereby all representing an attractive target to develop effective therapies in TNBC. Another weakness of TNBC is the presence of many immune cells, thereby immunotherapy represents another fascinating weapon to treat this incurable cancer.

This Special Issue aims to update the knowledge on TNBC and give new ideas for studying, developing, and testing new drugs.

I would like to invite you to contribute to this Special Issue with your research articles and reviews that include but are not limited to the following topics: molecular targets, signaling pathways, miRs, the role of epigenetics, new drugs, and targeted treatments in TNBC.

cancers

IMPACT FACTOR 4.5 | Indexed in: PubMed | CITESCORE 8.0

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
𝕏@Cancers_MDPI